Uses of Amitriptyline
Amitriptyline is a tricyclic antidepressant with FDA approval for depression, but is widely used off-label as a first-line agent for neuropathic pain, prophylaxis of moderate-to-severe cyclic vomiting syndrome, and chronic pain conditions including fibromyalgia and irritable bowel syndrome.
FDA-Approved Indication
Depression
- Starting dose: 75 mg/day in divided doses for outpatients, or 50-100 mg at bedtime 1
- Target dose: 150 mg/day for outpatients; hospitalized patients may require 200-300 mg/day 1
- Titration: Increase gradually in late afternoon/bedtime doses; therapeutic effect may take up to 30 days 1
- Maintenance: 50-100 mg/day (some patients require only 40 mg/day), preferably as single bedtime dose 1
- Duration: Continue for 3+ months after symptom relief to prevent relapse 1
Important: For adolescents and elderly patients, use lower doses: 10 mg three times daily with 20 mg at bedtime 1. Not recommended for children under 12 years 1.
Off-Label Uses (Guideline-Supported)
1. Neuropathic Pain (First-Line Agent)
Amitriptyline is recommended as a first-line coanalgesic for cancer-related and diabetic neuropathic pain, though evidence shows it is more efficacious than better-tolerated alternatives like nortriptyline. 2
Dosing for Neuropathic Pain:
- Starting dose: 10-25 mg at bedtime 2, 3, 4, 5
- Titration: Increase by 10-25 mg every 3-7 days as tolerated 2, 4
- Target dose: 50-150 mg at bedtime 2, 3, 4
- Maximum: 150 mg/day; doses >100 mg/day associated with increased cardiac death risk 3
Clinical considerations:
- Analgesic effect is independent of antidepressant activity and occurs at lower doses 2
- Onset of analgesia is earlier than antidepressant effect 2
- More efficacious than secondary amines (nortriptyline, desipramine) but with more anticholinergic side effects 2, 3
- Obtain ECG if PR or QTc prolongation suspected; avoid if prolonged 3
Evidence quality: While widely recommended in guidelines 2, 3, 4, 5, 6, a 2012 Cochrane review found no top-tier evidence, with only second-tier evidence showing benefit in diabetic neuropathy, mixed neuropathic pain, and fibromyalgia (NNT 4.6) 7. However, decades of clinical experience support continued use.
2. Cyclic Vomiting Syndrome Prophylaxis (First-Line)
The 2024 AGA guidelines strongly recommend amitriptyline as first-line prophylactic therapy for moderate-to-severe CVS (≥4 episodes/year, each lasting >2 days, requiring ED visits/hospitalizations). 8
Dosing for CVS:
- Starting dose: 25 mg at bedtime 8
- Titration: Increase by 10-25 mg every 2 weeks 8
- Target dose: 75-150 mg or 1-1.5 mg/kg at bedtime 8
Clinical considerations:
- Slow titration (10-25 mg increments every 2 weeks) is better tolerated 8
- Dosed at night due to sedative effects 8
- More anticholinergic/antihistaminergic activity than nortriptyline 8
- Monitor for prolonged QTc on ECG 8
The 2019 ANMS-CVSA guidelines also strongly recommend amitriptyline as first-line prophylaxis 9.
3. Chronic Pain Conditions
Irritable Bowel Syndrome (Second-Line)
The 2023 ATLANTIS trial demonstrated that low-dose amitriptyline (10-30 mg) is superior to placebo as second-line treatment for IBS in primary care when first-line therapies fail. 10
- Starting dose: 10 mg once daily 10
- Titration: Up to 30 mg once daily over 3 weeks based on symptoms and tolerability 10
- Duration: 6 months in trial; 20% discontinued due to adverse events 10
Headache/Migraine Prophylaxis
Real-world evidence from specialty headache practice shows most patients benefit from low doses (10-25 mg), with 75% reporting improvement and 85% persistence at follow-up. 11
- Most common dose: 10 mg daily (63% of patients started here) 11
- Maximum dose range: 2.5-100 mg daily, with most taking 10-25 mg 11
- Adverse effects: Daytime fatigue (11%) 11
General Chronic Pain
A 1993 dose-response study demonstrated that 75 mg provides significantly greater analgesia than 25 or 50 mg for chronic pain, though with higher adverse effect incidence. 12
4. Insomnia (Off-Label, Sleep Maintenance)
Low-dose amitriptyline (10-20 mg) is commonly prescribed off-label for insomnia with sleep maintenance problems, with 73.9% of patients reporting improvement in a 2023 study. 13
- Dose: 10-20 mg based on self-titration 13
- Effectiveness: 73.9% improved sleep maintenance, 31.3% improved sleep onset 13
- Side effects: 66.1% reported at least one side effect, but generally well-tolerated 13
5. Alzheimer's Disease-Related Depression
For agitated depression with insomnia in Alzheimer's patients 14:
- Starting dose: 10 mg at bedtime 14
- Maximum: 40 mg/day (given twice daily) 14
- More sedating than desipramine; useful for agitated depression 14
Common Adverse Effects (All Indications)
Anticholinergic effects are dose-dependent and include:
- Dry mouth (most common)
- Sedation/drowsiness
- Constipation
- Blurred vision
- Urinary hesitancy
- Weight gain
- Prolonged QTc interval 8, 2, 3, 1
Cardiac considerations:
- Doses >100 mg/day associated with increased sudden cardiac death risk 3
- Obtain baseline ECG in patients with cardiovascular disease or elderly patients 3
- Avoid if PR or QTc interval prolonged 3
Key Clinical Pearls
Dosing strategy varies by indication: Depression requires higher doses (75-150 mg) 1, while neuropathic pain, CVS prophylaxis, and chronic pain often respond to lower doses (10-75 mg) 8, 2, 4, 11, 10
Bedtime dosing preferred: Leverages sedative effects and minimizes daytime impairment 8, 1
Slow titration improves tolerability: Especially important in elderly patients and those with chronic pain 8, 2, 4
Plasma level monitoring: May be useful for suspected toxicity, non-compliance, or lack of response, though correlation with therapeutic effect is imperfect 1
Alternative to amitriptyline: Nortriptyline (secondary amine) has similar efficacy with fewer anticholinergic effects and is better tolerated 2, 3, 5
Patient selection matters: Elderly patients, those with cardiovascular disease, and those on multiple medications require extra caution and lower starting doses 3, 15, 1